Public Sector Pension Investment Board Has $4.71 Million Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Public Sector Pension Investment Board cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 236,720 shares of the biopharmaceutical company’s stock after selling 10,200 shares during the quarter. Public Sector Pension Investment Board’s holdings in Catalyst Pharmaceuticals were worth $4,706,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. GAMMA Investing LLC increased its position in Catalyst Pharmaceuticals by 62.1% during the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 681 shares during the period. nVerses Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter worth $50,000. Larson Financial Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares during the period. CWM LLC raised its position in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in shares of Catalyst Pharmaceuticals during the second quarter valued at about $70,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $22.07 on Monday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $13.00 and a twelve month high of $24.27. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 3.40 and a beta of 0.75. The firm’s 50-day simple moving average is $21.26 and its 200-day simple moving average is $18.79.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective on the stock. Truist Financial lifted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Citigroup increased their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $31.14.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.